VANCOUVER, British Columbia, Nov. 8, 2006 (PRIMEZONE) -- Zecotek Medical Systems Inc. (TSX-V:ZMS) (Frankfurt:W1I) today announced the official issuance of a U.S. patent for its LFS scintillation material. The U.S. patent number is 7,132,060.
"This represents a critical step for Zecotek to achieve market acceptance. This will particularly provide the PET and PET-CT manufacturers the required assurance to adopt the LFS crystal as an alternative high performance and cost effective scintillation material for their high resolution scanners. The granting of the LFS patent is a significant technical validation that will also offer Northrop Grumman, the Company's manufacturing and distribution alliance, an added technical validity to proceed confidently with the manufacturing and the World-wide sale of the LFS and its unique derivatives, under the assurance of a U.S. patent," stated Dr. Faouzi Zerrouk, Chairman and CEO.
About the Company
Zecotek Medical Systems Inc. is a market driven, Canadian research and development bio-photonics company. The Company is focused on the creation of advanced materials and integrated optoelectronic devices for high-resolution medical imaging, optical precision surgery, biopharmaceutical research, and 3D displays. The Company commercializes its technologies directly as well as through strategic alliances with leading OEM manufacturers and distributors. Zecotek's R&D facility in Singapore will create alliances and share in intellectual properties in a unique and growing industry. Shares of Zecotek are listed for trading on the TSX Venture Exchange under the symbol "ZMS."
For additional information on Zecotek Medical Systems and our technologies please see our Website at www.zecotekmed.com
The Zecotek Medical Systems company logo is available at http://www.primezone.com/newsroom/prs/?pkgid=3001